PCSK9 and ovarian carcinoma: Jacome Sanz Dafne et al. found that PF-06446846, a PCSK9-specific inhibitor, reduces LDL-C in plasma and inhibits ovarian cancer cell survival, while increased PCSK9 expression levels in ovarian cancer cells can induce AKT phosphorylation [24].